Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia
Lund, Sweden, August 18, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).
“This first commercial living donor transplant patient in Australia represents an important milestone for Hansa and for patients facing significant barriers to transplantation,” said Renée Aguiar-Lucander, CEO of Hansa Biopharma. “We look forward to continued collaboration with the Australian transplant community to build experience with Idefirix across both living and deceased donor transplantations.”
